Somatostatin inhibits exocrine pancreatic and has been used for treatment of pancreatic f i ~t u l a ~-~. The short ti, < 3 m i n in man6, and the risk of a rebound effect when treatment is interrupted7, require the peptide to be continuously infused intravenously. This may be circumvented by using
Evidence for using somatostatin analogues in the treatment of enterocutaneous fistula
β Scribed by P. Stevens; R. J. Delicata
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 88 KB
- Volume
- 98
- Category
- Article
- ISSN
- 0007-1323
- DOI
- 10.1002/bjs.7687
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The effects of somatostatin (SRIF) and its long-acting analogue, SMS 201-995 on the prevention and treatment of acute pancreatitis were studied in rats. Acute pancreatitis was established by ligating the bile duct at the point of entry into the duodenum, thereby allowing reflux of bile into the panc
I of a Somatostatin Analogue (Octreotide) in the Treatment of Patients with Asymptomatic Advanced Colon Cancer."' The disappointing results of this study contrast with recently reported cellular kinetic data for rectal cancer treatment with somatostatin. It should be noted that the dosage used in o